The following table shows the list of Johnson & Johnson clinical trials that can be included in a tranSMART search result.
|
Trial |
Title |
Platform |
|
C0168T37 |
A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis. |
Affymetrix Human Genome U133 Plus 2.0 array |
|
C0168T44 |
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with Plaque-type Psoriasis. |
Affymetrix Human Genome U133 Plus 2.0 array |
|
C0168T48 |
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (REMICADE®) in Subjects with Chronic Sarcoidosis with Pulmonary Involvement. |
RBM |
|
C0379T02 |
A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 1275) in Subjects with Moderate to Severe Psoriasis Vulgaris. |
DNA |
|
C0379T03 |
A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 1275) in Subjects with Relapsing Forms of Multiple Sclerosis. |
DNA |
|
C0379T07 |
A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn’s Disease. |
Affymetrix Human Genome U133 Plus 2.0 array |
|
C0524T03 |
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety Of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma. |
Affymetrix Human Genome U133 Plus 2.0 array |
|
C0743T10 |
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis. |
RBM |
|
C0743T12 |
A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis. |
Affymetrix Human Genome U133 Plus 2.0 array |
|
C0743X01` |
Detection of Mediators of Sarcoidosis Skin Lesions. |
Affymetrix Human Genome U133 Plus 2.0 array, RBM |